NCT06575075PHASE1, PHASE2Recruiting
Pilot Study of RR-HNK in OCD
Carolyn Rodriguez
Start Date
1/23/2026
Completion Date
11/30/2029
Summary
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
Detailed Description
This protocol examines the safety and efficacy of 2 dosage levels of intravenous RR-HNK administration in individuals with OCD.
Eligibility Criteria
Age Range: 18 years to 65 years
Inclusion Criteria:
* Ages 18-65
* Meet the criteria for OCD diagnosis
* Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI/CBT) or or had refused these treatments for individual reasons
* Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.
* Able to provide informed consent
Exclusion Criteria:
* Allergy or hypersensitivity to ketamine
* Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician
* Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
* Lifetime history of deep brain stimulation
Interventions
DRUG
RR-HNK/Hydroxynorketamine
DRUG
Placebo
Conditions
Obsessive-Compulsive Disorder
Locations
Stanford University School of Medicine
Palo Alto, California 94305
United States